#1 Clinical Trials Search in Europe

Study on the Safety and Effects of OMT-28 for Patients with Primary Mitochondrial Disease and Muscle or Heart Problems

2 1 1

What is this study about?

This clinical trial is focused on studying a condition known as Primary Mitochondrial Disease, which can lead to muscle problems, known as myopathy, and heart issues, referred to as cardiomyopathy. The trial will test a new treatment called OMT-28, which is taken as a capsule. The purpose of the study is to see how safe and tolerable this treatment is for patients, as well as to understand its effects on the body.

Participants in the study will take the OMT-28 capsule for a period of 12 weeks. During this time, researchers will monitor the patients to see if there is a significant improvement in their condition, specifically looking for a decrease in a marker called GDF-15, which is related to inflammation. The study will also keep track of any side effects or changes in health that might occur while taking the treatment.

The trial aims to gather important information about how OMT-28 works in people with Primary Mitochondrial Disease and whether it can help reduce symptoms associated with muscle and heart problems. This research is an important step in finding new ways to manage and treat this condition.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and performing necessary tests to ensure the patient meets the criteria for participation.

2 medication administration

The patient begins taking the study medication, OMT-28, which is provided in capsule form. The dosage is 24 mg, taken orally.

The medication is administered daily for a duration of 12 weeks.

3 monitoring and evaluation

Throughout the 12-week period, regular monitoring is conducted to assess the patient’s response to the medication.

This includes measuring levels of GDF-15, a marker used to evaluate the effectiveness of the treatment, aiming for a decrease of at least 20%.

4 safety assessments

Safety assessments are performed to monitor any adverse effects. This involves checking vital signs, conducting laboratory tests, and performing 12-lead ECGs.

The incidence, severity, and duration of any side effects are recorded and analyzed.

5 final evaluation

At the end of the 12-week treatment period, a final evaluation is conducted to determine the overall effectiveness and safety of the medication.

The primary endpoint is the number of patients showing a significant decrease in GDF-15 levels.

Who Can Join the Study?

  • Any gender, age 18 to 60 years
  • Must have a documented genetic change (mutation) that causes a mitochondrial disease. This includes specific changes like mitochondrial tRNA point mutations (such as m3243A>G, m8344A>G) and single mtDNA deletions.
  • Must have a diagnosis of Cardiomyopathy, which is a heart condition. This can be shown by LV hypertrophy (thickening of the heart muscle), LVEF<50% (a measure of how well the heart pumps), or late gadolinium enhancement on a heart MRI. Alternatively, must have Myopathy, a muscle condition, as defined by specific guidelines.
  • Must have a GDF-15 level between 1,200 to 10,000 pg/mL, which is a specific blood test result, measured at the start of the study.
  • Must be able to perform exercise tests.
  • Must be willing and able to sign an Informed Consent, which is a document that explains the study and confirms your agreement to participate. This includes agreeing to data protection requirements.
  • Must be able and willing to follow the study’s rules and requirements.
  • Female patients and female partners of male patients who can have children must agree not to become pregnant during the study and for 30 days after the last dose of the study medication.

Who Cannot Join the Study?

  • Patients who are not diagnosed with Primary Mitochondrial Disease cannot participate. This is a condition where the mitochondria, the energy-producing parts of cells, do not work properly.
  • Patients who are younger than 3 years old cannot participate.
  • Patients who are part of a vulnerable population, meaning they might need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Universita’ Di Pisa Pisa Italy
Friedrich Baur Institute An Der Neurologischen Klinik Und Poliklinik Munich Germany
Azienda Unita Sanitaria Locale Di Bologna Bologna Italy
Rheinische Friedrich-Wilhelms-Universitaet Bonn Bonn Germany
A.O.U. Policlinico G. Martino Di Messina Messina Italy
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Shilvioeo Rjhpleu Uosdpfpjey Mvutgae Czpypb Nijmegen The Netherlands
Mdgohlhntgbmhkvmrycxfdrhtv Hmyystbljxgqweea Halle (Saale) Germany

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not recruiting
01.06.2023
Italy Italy
Not recruiting
01.06.2023
The Netherlands The Netherlands
Not recruiting
01.06.2023

Trial locations

Investigated drugs:

OMT-28 is a medication being studied for its effects on patients with myopathy and/or cardiomyopathy, which are conditions affecting the muscles and heart. The trial aims to see if this medication can reduce inflammation and improve muscle and heart function. Researchers are also looking at how safe and tolerable the medication is for patients over a period of time.

Investigated diseases:

Primary Mitochondrial Disease – This is a group of disorders caused by dysfunctional mitochondria, the parts of cells responsible for energy production. These diseases can affect multiple systems in the body, leading to a wide range of symptoms. Commonly, they impact organs and tissues with high energy demands, such as the brain, muscles, and heart. Symptoms may include muscle weakness, neurological problems, and fatigue. The progression of the disease varies widely among individuals, with some experiencing mild symptoms and others facing more severe challenges. The variability in symptoms and progression makes it a complex condition to understand and manage.

Trial ID:
2023-508541-41-00
NCT ID:
NCT05972954
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of stopping heart failure medications in patients with non-ischemic cardiomyopathy who responded very well to cardiac resynchronization therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

    Recruiting

    2 1
    Investigated diseases:
    Austria Belgium France Germany Italy The Netherlands +3